A 52-year-old woman on warfarin for atrial fibrillation (INR 3.8) presents with recurrent epistaxis over 3 days. She denies trauma, nasal surgery, or prior epistaxis. On examination, the bleeding point is identified as a **single, bright-red, pulsatile vessel on the anterior nasal septum** (Little's area). Topical hemostasis with epinephrine and direct pressure for 10 minutes successfully stops the bleeding. What is the most likely underlying cause of this epistaxis?

Explanation

## Clinical Diagnosis Framework This case presents **anticoagulation-related epistaxis** with a clear temporal and clinical correlation: ### Key Diagnostic Features | Feature | Finding | Significance | |---------|---------|---------------| | **Anticoagulant** | Warfarin (INR 3.8 — supratherapeutic) | Direct causative agent | | **Bleeding site** | Single vessel, anterior septum (Little's area) | Common site for minor mucosal bleeding | | **Character** | Bright-red, pulsatile | Arterial source, not venous | | **Response to treatment** | Controlled with pressure + topical hemostasis | Indicates minor vessel, not systemic disease | | **No prior history** | First episode of epistaxis at age 52 | Acquired, not congenital | **High-Yield:** **Little's area** (Kiesselbach's triangle) is the most common site of anterior epistaxis because it is a highly vascularized anastomotic zone where branches of the **anterior ethmoidal, sphenopalatine, and superior labial arteries** converge. Minor mucosal trauma or anticoagulation can cause bleeding here. ## Why Anticoagulation Is the Cause **Key Point:** Warfarin at **INR 3.8 is supratherapeutic** (target for AF is 2.0–3.0). Elevated INR increases bleeding risk at any mucosal site. **Clinical Pearl:** Anticoagulation-related epistaxis typically presents as: 1. **Acute onset** in a patient on anticoagulants 2. **Single bleeding point** (localized mucosal vessel rupture) 3. **Responds to conservative measures** (pressure, topical hemostasis) 4. **No systemic features** (no telangiectasias, no vasculitis signs, no hypertensive crisis) ## Differential Diagnosis Exclusion ```mermaid flowchart TD A[Epistaxis in anticoagulated patient]:::outcome --> B{Single vessel or multiple sites?}:::decision B -->|Single, anterior septum| C[Likely anticoagulation-related]:::action B -->|Multiple telangiectasias| D[Consider HHT]:::outcome A --> E{Systemic symptoms?}:::decision E -->|Fever, rash, hemoptysis| F[Consider GPA]:::urgent E -->|None| G[Anticoagulation-related most likely]:::action A --> H{BP severely elevated?}:::decision H -->|Yes, >180/120| I[Hypertensive emergency]:::urgent H -->|No| G ``` ### Why Not the Other Diagnoses? **Hereditary Hemorrhagic Telangiectasia (HHT):** - Presents with **recurrent, spontaneous epistaxis** (✓ matches this case) - BUT: **multiple telangiectasias** visible on exam (not described here — single vessel noted) - Family history of HHT or recurrent bleeding from childhood (absent) - Mucocutaneous telangiectasias on lips, tongue, fingers (not mentioned) - **This patient has no prior epistaxis history at age 52** — HHT typically manifests earlier **Granulomatosis with Polyangiitis (GPA):** - Causes necrotizing vasculitis of small vessels - Presents with **systemic symptoms:** fever, malaise, arthralgias, hemoptysis, hematuria - **Nasal findings:** crusting, ulceration, septal perforation (not single bleeding vessel) - No systemic features in this case - c-ANCA/PR3 would be positive (not tested, but clinical picture doesn't fit) **Hypertensive Emergency:** - Requires **severely elevated BP** (typically >180/120 mmHg) - Causes **diffuse oozing** from multiple sites, not single pulsatile vessel - Patient's BP not documented as elevated - Hypertension alone does NOT cause epistaxis (common misconception) ## Management of This Patient **Immediate:** 1. **INR reversal:** Warfarin dose reduction or reversal (vitamin K 5–10 mg IV/PO) because INR 3.8 is supratherapeutic 2. **Local hemostasis:** Cautery (silver nitrate or electrocautery) of the bleeding vessel 3. **Anterior packing** if bleeding recurs **Follow-up:** - Recheck INR in 24–48 hours - Target INR 2.0–3.0 for AF - Consider switching to DOAC if recurrent anticoagulation-related bleeding **Mnemonic:** **WARFARIN epistaxis** features: - **W**arfarin (or other anticoagulant) on board - **A**cute onset in anticoagulated patient - **R**esponses to local hemostasis (pressure, cautery) - **F**ew bleeding sites (often single vessel) - **A**nterior location (Little's area common) - **R**ecurrent if INR not corrected - **I**NR supratherapeutic (>3.5) - **N**o systemic disease features [cite:Cummings Otolaryngology 6e Ch 41; Harrison 21e Ch 47]